Smooth operators

AI strengthens scalability in mid-sized pharma while preserving control

Mid-size pharmaceutical companies operate in one of the most complex environments in healthcare.

They pursue innovative therapies with the agility of smaller organisations yet face the same regulatory expectations, documentation standards and inspection scrutiny as global pharmaceutical giants.

These organisations must navigate the complex path of ambitious growth strategies supported by limited infrastructure and expanding pipelines while meeting regulators’ requests for transparency.

When regulatory strategy and clinical development fall out of sync, progress stalls. During this hiatus, teams can lose valuable time reconciling data across disparate systems and legacy technology stacks.

Compliance gaps emerge not from negligence but from fragmented systems and disconnected workflows. The business imperative is clear: mid-size pharma organisations must have access to scalable development models that strengthen execution without sacrificing agility.

For regulatory strategy and clinical development to stay connected, organisations must adopt a more proactive approach. This includes developing inspection-ready environments where documentation, review and accountability all take priority.

With this stance, reactive compliance practices such as late-stage documentation review can be retired for good.

The traditional approach to growth by mid-size companies included layering point solutions onto existing workflows.

This meant onboarding additional staff to manage peaks in workload or deploying advanced tools to bridge gaps in either regulatory or clinical operations.

While this approach succeeds in providing short-term relief, it comes at the price of introducing new silos, increasing handoffs and reducing visibility across the product life cycle.

Over time, disconnected systems make it harder to maintain a clear view of programme status, forcing teams to track manual workflows instead of receiving real-time insights.

At a time when pipelines are expanding, this breakdown in coordination can hinder decision-making and increase the likelihood of inconsistencies across submissions.

An updated, integrated model provides a clearer and more sustainable path forward. When clinical development, regulatory strategy and life cycle management operate within a coordinated framework, mid-sized organisations can reduce friction and accelerate decision-making.

When layers of information are structured, connected and accessible across different functions, teams can respond to regulatory inquiries quickly, establish a consistent standard and reduce the number of errors that often emerge when systems operate in isolation.

Organisation-wide alignment ensures that regulatory strategies and clinical design are approached proactively, reducing costly rework and shortening submission timelines.

Globally, no two regulatory markets are the same and they are always evolving.  However, the one constant that both mid-sized and large pharmaceutical organisations can rely on is the expectation to submit comprehensive documentation, maintain transparent data governance and ensure consistent life cycle management.

Everything from labelling updates to chemistry manufacturing and controls variations to renewals and marketing authorisation transfers must be thoroughly documented and requires disciplined oversight.

These expectations continue to rise as regulatory authorities place stronger emphasis on data integrity and traceability of information being reviewed and approved throughout the life cycle.

Today’s clinical research organisations must be prepared to show not only the path to how these decisions were made but also who made them.

When strategic functions operate across fragmented environments, teams spend valuable time and resources reconciling records instead of advancing programmes. Now, when done on a global scale, each additional indication or geographic expansion compounds complexity.

Eventually, operations become so hindered that submissions are delayed, compliance risks increase dramatically and commercialisation opportunities are lost.

Instead of treating regulatory operations as an administrative burden, forward-thinking organisations view them as a competitive advantage. By investing in real-time regulatory intelligence, structured submission planning and coordinated life cycle management, these organisations can develop workflows and therapies on the foundation of inspection readiness.

In the event of an audit, disruptions can be effectively mitigated, teams are better positioned with health authorities and enterprise value is protected.

Organisations that operate with this level of readiness are also better equipped to adapt to sudden changes in requirements. To achieve this, they are building their processes with consistent data, standardised review models and clear governance rather than manual workarounds.

Another modern asset for mid-sized pharmaceutical organisations is the investment in and growth of artificial intelligence. When developed and integrated with intent, AI augments research teams and enhances regulatory and clinical workflows without requiring massive infrastructure expansion.

It is estimated that 40% of an organisation’s capacity could be freed up as agentic AI enhances or automates routine or knowledge-based tasks. Mid-size organisations typically see impact in three areas:

• Regulatory and clinical authoring: AI-assisted drafting accelerates document preparation while subject-matter experts retain control over review and final approval
• Regulatory intelligence and planning: by ingesting and analysing volumes of historical agency feedback, machine learning models can anticipate questions and mitigate risk earlier in development
• Operational transparency: integrated data environments improve visibility across clinical, regulatory and commercial functions, which reduces silos and enhances collaboration.

Mid-sized pharmaceutical companies do not need to replicate the infrastructure of large pharma teams to compete effectively. What they need are models that are scalable without diluting the agility they are known for.

Leveraging integrated development frameworks in conjunction with AI-empowered workflows allows mid-sized pharma teams to break into new markets, build out their pipelines and manage complex life cycles without breaking budgets.

This balanced approach allows teams to focus on valuable outcomes instead of administrative reconciliation. From a leadership perspective, organisations can scale programmes confidently while maintaining fiscal discipline.

Most importantly, it supports faster access to therapies that improve patient outcomes.

Execution with precision is what the pharmaceutical landscape thrives on. By replacing fragmentation with coordination and embedding intelligence into everyday workflows, pharmaceutical companies transform operational risk into strategic advantage.

Michelle Gyzen is Senior Director of Strategic Regulatory Solutions at IQVIA